Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction
Bonti, a privately-held, clinical-stage biotechnology company, today announced the initiation of the SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. The first clinical study, SHINE-1, is a randomized, placebo-controlled, double-blind, parallel arm trial to evaluate the safety and efficacy of EB-001 injections in patients undergoing Mohs micrographic surgery on the forehead. [...]
Bonti Announces Close of $15.5 Million Series C Funding and Appointment of David Ramsay as Chief Financial Officer
Latest Financing to Enable Continued Clinical Development of Lead Product EB-001 to Treat Musculoskeletal Pain Bonti, a privately-held, clinical-stage biotechnology company, today announced it successfully closed a $15.5 million Series C financing, bringing the cumulative investment in the Company to over $36 million. Capital from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its [...]
Fauad Hasan, CEO and Co-founder, to Spotlight the Company in San Francisco Bonti, a privately-held, clinical-stage biotechnology company, today announced that Fauad Hasan, CEO and co-founder, will present at the following in San Francisco the same week as the 36th Annual J.P. Morgan Healthcare Conference: The Neuroscience Innovation Forum on Sunday, January 7th at 1:50 PM (PT) The 5th Annual [...]
Fauad Hasan, Co-founder and CEO, to Provide Bonti Highlights on November 29th in New York City Bonti, a privately-held, clinical-stage biotechnology company, today announced that Fauad Hasan, co-founder and CEO, is scheduled to present at the Piper Jaffray 29th Annual Healthcare Conference. The conference is taking place November 28th and 29th at the Lotte New York Palace Hotel in New [...]
Could a botulinum neurotoxin be a game changer to opioids for treating pain? The novel serotype E botulinum neurotoxin EB-001 for treating focal musculoskeletal pain is the lead product candidate of biotech company Bonti Inc. (Newport Beach, Calif.).
While the aesthetics industry has been focused on new botulism toxin products and dosing strategies geared toward increasing longevity of results, a new company Bonti has been developing EB-001, a serotype E botulinum toxin that moves in the opposite direction.